308 related articles for article (PubMed ID: 25647729)
1. Mucosal effects of tenofovir 1% gel.
Hladik F; Burgener A; Ballweber L; Gottardo R; Vojtech L; Fourati S; Dai JY; Cameron MJ; Strobl J; Hughes SM; Hoesley C; Andrew P; Johnson S; Piper J; Friend DR; Ball TB; Cranston RD; Mayer KH; McElrath MJ; McGowan I
Elife; 2015 Feb; 4():. PubMed ID: 25647729
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
McGowan I; Hoesley C; Cranston RD; Andrew P; Janocko L; Dai JY; Carballo-Dieguez A; Ayudhya RK; Piper J; Hladik F; Mayer K
PLoS One; 2013; 8(4):e60147. PubMed ID: 23573238
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
[TBL] [Abstract][Full Text] [Related]
4. Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression.
Romas L; Birse K; Mayer KH; Abou M; Westmacott G; Giguere R; Febo I; Cranston RD; Carballo-Diéguez A; McGowan I; Burgener A
AIDS Res Hum Retroviruses; 2016; 32(10-11):1005-1015. PubMed ID: 27316778
[TBL] [Abstract][Full Text] [Related]
5. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Dobard CW; Sharma S; Cong ME; West R; Makarova N; Holder A; Pau CP; Hanson DL; Novembre FJ; Garcia-Lerma JG; Heneine W
Retrovirology; 2015 Aug; 12():69. PubMed ID: 26253002
[TBL] [Abstract][Full Text] [Related]
8. Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.
Richardson-Harman N; Hendrix CW; Bumpus NN; Mauck C; Cranston RD; Yang K; Elliott J; Tanner K; McGowan I; Kashuba A; Anton PA
PLoS One; 2014; 9(10):e111507. PubMed ID: 25350130
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).
Hiruy H; Fuchs EJ; Marzinke MA; Bakshi RP; Breakey JC; Aung WS; Manohar M; Yue C; Caffo BS; Du Y; Abebe KZ; Spiegel HM; Rohan LC; McGowan I; Hendrix CW
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1098-108. PubMed ID: 26227279
[TBL] [Abstract][Full Text] [Related]
10. Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates.
Girard L; Birse K; Holm JB; Gajer P; Humphrys MS; Garber D; Guenthner P; Noël-Romas L; Abou M; McCorrister S; Westmacott G; Wang L; Rohan LC; Matoba N; McNicholl J; Palmer KE; Ravel J; Burgener AD
Sci Rep; 2018 May; 8(1):8059. PubMed ID: 29795295
[TBL] [Abstract][Full Text] [Related]
11. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
12. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Keller MJ; Madan RP; Torres NM; Fazzari MJ; Cho S; Kalyoussef S; Shust G; Mesquita PM; Louissaint N; Chen J; Cohen HW; Diament EC; Lee AC; Soto-Torres L; Hendrix CW; Herold BC
PLoS One; 2011 Jan; 6(1):e16475. PubMed ID: 21283552
[TBL] [Abstract][Full Text] [Related]
14. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
15. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
[TBL] [Abstract][Full Text] [Related]
17. Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
Thurman AR; Chandra N; Yousefieh N; Kimble T; Anderson SM; Cottrell M; Sykes C; Kashuba A; Schwartz JL; Doncel GF
J Acquir Immune Defic Syndr; 2018 May; 78(1):82-92. PubMed ID: 29424790
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.
Gupta SK; Nutan
HIV AIDS (Auckl); 2013 Oct; 5():295-307. PubMed ID: 24174883
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ; Uckun FM
Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
[TBL] [Abstract][Full Text] [Related]
20. HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Garrett NJ; Werner L; Naicker N; Naranbhai V; Sibeko S; Samsunder N; Gray C; Williamson C; Morris L; Abdool-Karim Q; Abdool-Karim SS
J Acquir Immune Defic Syndr; 2015 Jan; 68(1):55-61. PubMed ID: 25247433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
